adaptive biotechnologies stock buy or sell
Current Price 934 Target Price 1429 530 Upside 5 36 Adaptive Biotechnologies Stock. ADPT Stock Price Prediction.
Goldman Sachs These 2 Stocks Are Poised To Surge By At Least 30
One investment analyst has rated the stock with a sell rating three have given a hold rating and.
. About ADPT Adaptive Biotechnologies Corp. Adaptive Biotechnologies ADPT Stock - Buy or Sell. The stock was sold at an.
848 000 000 758 PM ET Add to. The average price target is 1350 with a high. According to the issued ratings of 8 analysts in the last year the consensus rating for Adaptive Biotechnologies stock is Moderate Buy based on the current 3 hold ratings and.
As of 2022 November 14 Monday current price of ADPT stock is 8800 and our data indicates that the asset price has. In other news insider Nitin Sood sold 31066 shares of Adaptive Biotechnologies stock in a transaction on Tuesday November 1st. Adaptive Biotechnologies Corp ADPT stock is down -176 while the SP 500 has gained 023 as of 1207 PM on Friday Nov 18.
Adaptive Biotechnologies appears a compelling earnings-beat. Set your investment goals. An upward trend in earnings estimates -- one of.
97 rows About the Adaptive Biotechnologies Corp. The Analyst Adaptive Biotechnologies ADPT Exchange. 4 easy steps on how to buy 1HMF Stock.
You can buy or sell ADPT and other ETFs options and stocks. Buy or sell Adaptive Biotechnologies stock pre IPO via an EquityZen fund EquityZen EquityZen is a marketplace for shares of proven pre IPO tech companies View More. Engages in the development of an immune medicine platform.
A daptive Biotechnologies ADPT could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank 2 Buy. Adaptive Biotechnologies Price Targets What analysts think ADPT stock price will be. ADPT is down -015 from the.
How to Invest in Adaptive Biotechnologies Stock. Nearly 040 of Adaptive Biotechnologies Corporations shares belong to company insiders and institutional investors own 8750 of the companys shares. Whether a long-term investor or a day trader your plan should detail your profit expectation and the stop-loss.
Learn more about whether Adaptive Biotechnologies Corp is a good stock to buy or sell based on recent news as well as its key financial metrics. By selling US514k worth of Adaptive Biotechnologies Corporation NASDAQADPT stock at an average sell price of US1183 over the last year insiders. Adaptive Biotechnologies ADPT Delayed Data from NSDQ 848 USD -086 -921 Updated Nov 14 2022 0400 PM ET After-Market.
The average twelve-month price prediction for Adaptive Biotechnologies is 2164 with a high price target of 5000 and a low price target of 750. Read on to find out how. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before theyve reported.
Based on 4 Wall Street analysts offering 12 month price targets for Adaptive Biotechnologies in the last 3 months. Is Adaptive Biotechnologies Corp NASDAQADPT stock a buy or a sell. ADPT is owned by 9320 institutional shareholders 5930 Adaptive Biotechnologies insiders and 000 retail investors.
Do Insiders Own Shares In Adaptive Biotechnologies Corporation Nasdaq Adpt
Seattle Inno Adaptive Biotechnologies To Receive Up To 250m In Financing Deal
Biotech Stocks Are Getting Crushed But Industry Insiders Say There S Reason For Optimism Geekwire
Comprehensive T Cell Repertoire Characterization Of Non Small Cell Lung Cancer Nature Communications
How To Buy Adaptive Biotechnologies Adpt Nasdaq Shares In Australia Finder
Adpt Stock Forecast Price News Adaptive Biotechnologies
Adaptive Biotech Plans 230 Million Ipo To Advance Immune Sequencing Technologies Biospace
Here S Why Adaptive Biotechnologies Soared 61 7 In The First Half Of 2020 The Motley Fool
Adpt Stock Forecast Price News Adaptive Biotechnologies
Adaptive Biotechnologies Corporation Adpt Stock Price Quote News Stock Analysis
Seattle S Adaptive Biotechnologies Upsizes Stock Offering On Strong Investor Interest The Seattle Times
Adaptive Biotechnologies And Microsoft Expand Partnership To Decode Covid 19 Immune Response And Provide Open Data Access Adaptive Biotechnologies
Is A Surprise Coming For Adaptive Biotechnologies Adpt This Earnings Season
Adaptive Biotech T Cell Test Receives Fda Approval For Emergency Use
Big Debut Shares Of Adaptive Biotechnologies Rise 100 On First Day As Public Company Geekwire
Adaptive Biotechnologies Goes Public In 300m Offering Puget Sound Business Journal
S 1
Biotech Companies Soar In Stock Market Debuts Wsj
Adaptive Biotechnologies Employee Benefits And Perks Glassdoor